SEC Tracker
Get the app

Perspective Therapeutics CATX

Perspective Therapeutics reported a $32.44 million net loss for Q3 2026.

Perspective Therapeutics (CATX) filed a 10-Q with the SEC on Nov 9, 2026, 4:35 pm ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Net loss: $32.44 million for the three months ended Sep 30, 2026
  2. Diluted EPS: -$0.27 for the three months ended Sep 30, 2026
  3. Cash and equivalents: $41.04 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Perspective Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

No new risk factors or legal mentions.

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Operating income and margin−$34.32M−$29.26M−17%
Net income−$32.44M−$26.79M−21%
Operating cash flow−$31.35M−$20.65M−52%
Cash$41.04M$48.49M−15%

Data on this page was fetched . The filing on SEC.gov is the record.